Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
7.9.2023 10:00:00 EEST | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.
Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.
CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.
CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.
Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.”
Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: “ We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.
We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.
Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.
For more information visit www.cerbaresearch.com
About CIRION
CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).
Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907759314/en/
Contact information
Press contacts:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com
CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze InSpire Reduces Token Maxxing, Turning Runaway AI Costs Into Predictable Enterprise Value28.7.2026 16:03:00 EEST | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Mindbreeze InSpire reduces token maxxing, the costly overconsumption of large language model (LLM) tokens that is straining enterprise AI budgets. By retrieving only the most relevant, grounded content and passing it to LLMs with precision, Mindbreeze InSpire lowers the tokens required per answer while improving accuracy, giving enterprises a path to scalable AI with predictable economics. Token maxxing has become one of the most underestimated risks in enterprise AI. As organizations connect generative AI to their data, many default to injecting large volumes of undifferentiated context into every prompt, repeatedly, across thousands of queries. Industry analysis has warned that tokens are becoming the true unit of AI cost, with usage-driven and nonlinear spending that is difficult to forecast and quick to erode margins. The problem is rarely the model. It is what the model is asked
Uptime Institute 16 th Annual 2026 Global Data Center Survey: Deployment of High Density Racks Rising Fast, Operators Face Continued Recruiting and Retention Pressures28.7.2026 16:02:00 EEST | Press release
Uptime Institute today released the findings of its 16th Annual Global Data Center Survey, the most comprehensive study of the digital infrastructure sector. The 2026 results reveal an industry navigating workforce constraints, escalating outage expenses, even as rising costs remain the top concern for management teams. Financial Pressure and Resource Constraints Intensify: While high costs continue to be a primary concern for data center leaders, the 2026 survey also highlights escalating concerns over capacity forecasting, power availability, and supply chain disruptions. Power efficiency gains remain gradual. The industry saw minor improvements in average Power Usage Effectiveness (PUE) levels this year. While newer facilities may boast highly efficient designs, overall global progress is slowed by legacy infrastructure. The AI and Density Reality Check: Despite market enthusiasm for Artificial Intelligence, expectations for AI in data center operations cooled slightly in 2026. Oper
Torq Unveils the SOC Brain: The AI SOC That Learns, Not Just Remembers28.7.2026 16:00:00 EEST | Press release
Torq, the established agentic security operations leader, today introduced Torq SOC Brain™, a new layer of the Torq AI SOC Platform that continuously learns from historical investigations, analyst decisions, and organization-specific security operations to create a unified, self-learning AI SOC. While most autonomous investigation systems claim to be self-learning, they are, in reality, memory systems—they simply retrieve past cases and pass them to a language model at decision time. Torq SOC Brain is fundamentally different. It reasons from precedent, adapts to how each SOC evaluates risk, and continuously refines its judgment with every completed investigation. The result is an AI SOC that grows more accurate over time—not a thin wrapper around a generic AI model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728408536/en/ Torq SOC Brain demos are available for qualified Black Hat USA 2026 attendees at the Torq booth a
AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street28.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that AUTOBACS SEVEN Co., Ltd. celebrates its 10-year partnership with Rimini Street, marking a decade of stable core operations and reinvestment in innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728266493/en/ AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street Since switching to Rimini Support™ for SAP ECC 6 in 2016, AUTOBACS SEVEN has expanded its partnership to include Oracle Database, helping the company stabilize mission-critical systems, reduce maintenance burden and free resources for innovation. “At AUTOBACS SEVEN, our leadership team meets regularly to discuss how we will grow as a company over the next five to ten years. During these conversations, we talk openly about how to be
Abnormal AI Extends its Behavioral Security Platform to Identity and AI Security28.7.2026 16:00:00 EEST | Press release
Abnormal AI, the AI-native behavior security company trusted by more than 25% of the Fortune 5001, today announced the expansion of its Behavioral Security Platform across the enterprise, introducing three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention. Together, the launch extends the behavioral AI that already secures over 4,500 customers1 to the identities, AI systems and onboarding pipeline that attackers increasingly exploit. Additionally, customers can now activate products from the AI App Store, a new interface to turn on Abnormal products in a single click. For nearly a decade, Abnormal has protected organizations by understanding behavior, learning what normal looks like for every identity and detecting the deviations that signal anomalous activity or an attack. That behavioral foundation spanning email, sign-in, and communication signals, now extends across the enterprise identity attack surface. “Abnormal envisioned a future where behavi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom